<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28500" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Reversible Cerebral Vasoconstriction Syndromes</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nesheiwat</surname>
            <given-names>Omar</given-names>
          </name>
          <aff>Riverside Community Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al-Khoury</surname>
            <given-names>Lama</given-names>
          </name>
          <aff>UCRSOM</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omar Nesheiwat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lama Al-Khoury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28500.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Reversible cerebrovascular syndrome (RCVS) is a rare and often underrecognized cerebrovascular&#x000a0;condition characterized by sudden and severe headaches that occur over days to weeks due to underlying widespread reversible cerebral arterial vasoconstriction. These headaches reach peak intensity within the first minute and&#x000a0;are often described as "thunderclap" headaches.&#x000a0;Although&#x000a0;typically benign and self-limited, RCVS can lead to severe complications such as ischemic stroke, subarachnoid hemorrhage, and posterior reversible encephalopathy syndrome. RCVS is commonly triggered by eclampsia and certain medications, particularly vasoconstrictive and chemotherapeutic agents.</p>
        <p>Diagnosis of RCVS is supported by cerebral angiography, which reveals the classic "sausage on a string" appearance of constricted cerebral arteries, although initial neuroimaging might not show abnormalities. Management of RCVS involves removing potential triggers, controlling symptoms such as headaches and seizures, and managing blood pressure.&#x000a0;This activity reviews diagnostic imaging modalities, their interpretation, and evidence-based treatment approaches for RCVS, including medication management and lifestyle modifications, with an emphasis on the potential triggers, risk factors, and clinical presentations associated with RCVS.&#x000a0;This activity provides healthcare providers the knowledge and skills to accurately and promptly diagnose RCVS, differentiate it from other cerebrovascular disorders, and initiate appropriate management strategies.&#x000a0;In addition, this activity will explore strategies for patient education and follow-up care to ensure optimal outcomes and prevent recurrences, emphasizing the importance of diagnostic criteria and imaging interpretation to avoid misdiagnosis and unnecessary interventions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify clinical manifestations and diagnostic criteria specific to reversible cerebral vasoconstriction syndrome to facilitate timely recognition.</p></list-item><list-item><p>Screen patients presenting with sudden-onset "thunderclap" headaches for potential reversible&#x000a0;cerebral&#x000a0;vasoconstriction&#x000a0;syndrome triggers, including medications and physiological stressors.</p></list-item><list-item><p>Apply appropriate treatment modalities for reversible&#x000a0;cerebral&#x000a0;vasoconstriction&#x000a0;syndrome complications, such as ischemic stroke or subarachnoid hemorrhage, based on clinical severity.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams, including neurologists, radiologists, and pharmacists, to coordinate comprehensive care for patients with reversible&#x000a0;cerebral&#x000a0;vasoconstriction&#x000a0;syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28500&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28500">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28500.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by sudden explosive and severe headaches that occur over days to weeks due to underlying widespread cerebral vasoconstriction. Although&#x000a0;typically benign and self-limited, RCVS can lead to severe complications such as&#x000a0;ischemic stroke, convexity subarachnoid or other intracerebral hemorrhage, and posterior reversible encephalopathy syndrome (PRES).<xref ref-type="bibr" rid="article-28500.r1">[1]</xref></p>
        <p>RCVS is now understood as a syndrome of cerebrovascular dysregulation. This condition is characterized by severe, sudden-onset headaches, often described as "thunderclap" headaches (TCHs), with peak intensity typically reached within the first minute. Recurrent TCHs are diagnostic of RCVS. Triggers, especially eclampsia or vasoconstrictive and many chemotherapeutic agents, have been recognized. RCVS is almost always reversible and self-limited in its clinical course.</p>
        <p>RCVS is a descriptive term subsumed with the PRES under the designation of cerebrovascular dysregulation. Both syndromes feature similar clinical and imaging manifestations, including headaches, visual symptoms, seizures, and confusion. Management of the condition includes removal of any triggers, symptomatic treatment of headaches and seizures, and control of moderate blood pressure.</p>
        <p>RCVS, which likely results from endothelial dysfunction and abnormal cerebrovascular tone, can be visualized on cerebral angiography, where the constriction of cerebral arteries presents a classic "sausage on a string" appearance. However, structural neuroimaging is frequently unrevealing, especially in the early stages.</p>
        <p>Before the recognition and description of RCVS, many patients were misidentified as having primary angiitis of the central nervous system (PACNS) and, consequently, were exposed to the risks of brain biopsy and chronic immunosuppression. Better characterization of RCVS through diagnostic scores, such as the RCVS<sub>2</sub> score (described below), has&#x000a0;significantly eliminated this confusion.</p>
      </sec>
      <sec id="article-28500.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The relationship between recurrent TCHs and dynamic cerebral artery narrowing in RCVS is poorly understood. Some theories suggest the involvement of trigeminovascular or serotonergic pathways connecting the cerebral vessels and the brainstem as the underlying culprits.<xref ref-type="bibr" rid="article-28500.r2">[2]</xref></p>
        <p>Systemic hypertension may contribute to the blood-brain barrier breakdown commonly observed in cerebral dysregulation syndrome.</p>
        <p>Numerous RCVS triggers have been identified, many of which feature increased sympathetic tone. Prominent among them are primary headache disorders, especially those of the exertional variety. Women are vulnerable to RCVS during late pregnancy and in the puerperium; eclampsia and pre-eclampsia are&#x000a0;additional risk factors. Many drugs&#x02014;both licit and illicit&#x02014;have been associated with RCVS. Illicit drugs such as cocaine, ecstasy, amphetamines, cannabis, and LSD are reportedly known triggers. The list of licit drugs is legion and includes anticholinergic agents, antimigraine medications, cough and cold suppressants, antidepressants, adrenergic agents, blood products, chemotherapeutic and immune-modulatory agents, hormonal agents, and anti-protozoal medications. Common substances such as coffee, eucalyptus, and licorice can also precipitate RCVS.</p>
        <p>Other potential triggers of RCVS include tumors such as pheochromocytoma and paraganglioma, trauma, head and neck surgery, and carotid dissection. Medical conditions, including antiphospholipid antibody syndrome and thrombotic thrombocytopenic purpura (TTP), can also be potential triggers of RCVS.<xref ref-type="bibr" rid="article-28500.r3">[3]</xref><xref ref-type="bibr" rid="article-28500.r4">[4]</xref>&#x000a0;The onset of RCVS after exposure to triggers can&#x000a0;range between a few days to several months.<xref ref-type="bibr" rid="article-28500.r5">[5]</xref><xref ref-type="bibr" rid="article-28500.r6">[6]</xref></p>
        <p>Although definitive genetic risk factors for RCVS have not been conclusively identified, occasionally, this condition has been observed in patients with underlying genetic diseases, such as adult-onset Leigh syndrome.<xref ref-type="bibr" rid="article-28500.r7">[7]</xref>&#x000a0;A single study reported that the Val66Met polymorphism in brain-derived neurotrophic factors may influence RCVS, with patients carrying the Val allele showing higher mean vasoconstriction scores across all arterial segments than MetMet homozygotes.<xref ref-type="bibr" rid="article-28500.r8">[8]</xref></p>
      </sec>
      <sec id="article-28500.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Although RCVS is considered a rare condition, it has received growing attention in peer-reviewed medical literature&#x000a0;over the past 20 years. In 2003, 3 published studies focused on RCVS; by 2023, this number had risen to 80. However, due to the absence of large-scale epidemiological studies, the actual incidence and prevalence of RCVS remain poorly understood. The incidence is likely increasing due to a combination of increased awareness of the condition among clinicians and the widespread use of vascular and magnetic resonance imaging (MRI).<xref ref-type="bibr" rid="article-28500.r9">[9]</xref>&#x000a0;A 2019 study published in the journal <italic toggle="yes">Stroke</italic> estimated the incidence to range widely from 7% to 54%, highlighting significant variability in reported cases.<xref ref-type="bibr" rid="article-28500.r10">[10]</xref>&#x000a0;</p>
        <p>RCVS predominantly affects adult women with female-to-male ratios ranging from 2:1 to 10:1, even after accounting for postpartum cases. Interestingly, male predominance is observed in children. The age range of RCVS patients is vast&#x02014;ranging from infancy to the early 80s&#x02014;but in reported cohort studies, the mean age of onset was in the fifth decade of life.<xref ref-type="bibr" rid="article-28500.r2">[2]</xref></p>
        <p>As our understanding of cerebral dysregulation has improved over the past 2 decades, the term "RCVS" has replaced many previous terms, including benign angiopathy of the CNS; cerebral vasoconstriction associated with drugs, chemotherapeutic agents, and immune modulators; Call syndrome; Call-Fleming syndrome; postpartum cerebral angiopathy; migraine angiitis; and CNS pseudovasculitis.<xref ref-type="bibr" rid="article-28500.r10">[10]</xref><xref ref-type="bibr" rid="article-28500.r2">[2]</xref></p>
      </sec>
      <sec id="article-28500.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The underlying pathophysiology of RCVS remains enigmatic and poorly understood, similar to its incidence and prevalence. An emerging consensus suggests that transient dysregulation of cerebral vascular tone leads to the multifocal vasoconstriction and dilatation seen in the syndrome. Endothelial dysfunction, sympathetic hyperstimulation, and oxidative stress are prominent factors and pathogenic mechanisms implicated in RCVS.<xref ref-type="bibr" rid="article-28500.r11">[11]</xref><xref ref-type="bibr" rid="article-28500.r12">[12]</xref> Recent pathophysiological studies have increasingly highlighted disruptions to the blood-brain barrier as a consequence of endothelial dysfunction.<xref ref-type="bibr" rid="article-28500.r1">[1]</xref></p>
      </sec>
      <sec id="article-28500.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Commonly, patients with RCVS present with symptoms of an explosive headache that reaches peak intensity within 1 minute of onset, known as a TCH. The TCH recurs in up to 85% to 90% of patients, typically occurring roughly weekly for up to 4 weeks, with a decrease in intensity and frequency during that time span.<xref ref-type="bibr" rid="article-28500.r2">[2]</xref>&#x000a0;Clinicians should suspect RCVS in any patient presenting with a TCH. A thorough headache history should be obtained, with particular attention to any prior history of migraine headaches and any reported changes in the pattern of headaches.</p>
        <p>Seizures and neurological focality may emerge within the first 10 days of recurrent headaches, and such a history should always be sought. Focal symptoms such as aphasia and hemiparesis may indicate an underlying brain injury, typically ischemic or hemorrhagic complications. Visual symptoms are common, including blurriness, cortical blindness, and scotomas.</p>
        <p>Indicators of generalized neurological dysfunction include seizures and encephalopathy. The latter is likely a consequence of intolerable headache pain, as it tends to be mild and of limited duration. When present, seizures are typically generalized with tonic-clonic features and are usually self-limited. Seizures occur less frequently in RCVS compared to PRES, another well-characterized syndrome of cerebrovascular dysregulation. &#x000a0;</p>
        <p>A history of potential triggers must always be sought, including a surgical history, particularly neurosurgery, recent childbirth, a thorough medication history, social history, and&#x000a0;sexual history. Regarding medications, it is essential to inquire about the use of vasoactive substances, particularly adrenergic agonists and serotonergic agents.<xref ref-type="bibr" rid="article-28500.r13">[13]</xref>&#x000a0;Similarly, inquiring about the use of recreational substances, both licit (eg, cannabis) and illicit (eg, cocaine and amphetamines) is mandatory.&#x000a0;Although RCVS has not been linked to causative underlying genetic mechanisms to date, family history should always be sought, as RCVS has been associated with other heritable conditions, such as pheochromocytoma and porphyria.<xref ref-type="bibr" rid="article-28500.r14">[14]</xref></p>
        <p>A 2019 study, based on a retrospective analysis of 202 consecutive patients with arteriopathy in the Massachusetts General Hospital's Research Patient Database Repository, described an RCVS<sub>2 </sub>score. With a maximal score of 10 (range -2 to 10), the RCVS<sub>2 </sub>score includes the following 5 factors:</p>
        <list list-type="bullet">
          <list-item>
            <p>The presence of TCH</p>
          </list-item>
          <list-item>
            <p>Involvement of the intracranial carotid artery</p>
          </list-item>
          <list-item>
            <p>Female sex</p>
          </list-item>
          <list-item>
            <p>An identified vasoactive trigger</p>
          </list-item>
          <list-item>
            <p>The presence of subarachnoid hemorrhage.</p>
          </list-item>
        </list>
        <p>TCH alone engenders a score of 5. Scores of 5 or higher showed 90% sensitivity and 99% specificity for diagnosing RCVS.<xref ref-type="bibr" rid="article-28500.r15">[15]</xref></p>
      </sec>
      <sec id="article-28500.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>After obtaining a history focused on possible triggers of the TCH, recent use of medications and substances, and any history of recent confusion or seizures, a thorough neurological examination must be performed, assuming the patient is hemodynamically stable. This examination should focus particularly on determining the level of consciousness and mental acuity, the presence of visual signs, and other localizing findings such as aphasia, neglect, hemiparesis, and hemisensory loss. Diffuse hyperreflexia is common and likely reflects a combination of underlying serotonergic activity and autonomic dysregulation.<xref ref-type="bibr" rid="article-28500.r16">[16]</xref></p>
        <p>Over 70% of RCVS patients have normal structural brain imaging at presentation. Within the ensuing 2 weeks, approximately 70% of hospitalized patients will develop either subarachnoid or parenchymal hemorrhage, ischemic stroke, or vasogenic edema, with hemorrhagic insults generally occurring earlier than the ischemic variety. Edema and ischemia are seen preferentially in the posterior watershed regions, the cerebellum, and the cortical-subcortical regions of the parietooccipital and frontal lobes, while deep structures are rarely affected.</p>
        <p>The nature of the TCH can effectively guide the initial steps in a workup. When the TCH is recurrent&#x02014;as tabulated by the RCVS<sub>2 </sub>score&#x02014;the pretest probability of RCVS is functionally 100%, essentially obviating the need for additional invasive diagnostic procedures such as lumbar puncture or brain biopsy.<xref ref-type="bibr" rid="article-28500.r15">[15]</xref></p>
        <p>In cases of a single TCH, potentially fatal underlying conditions must be ruled out. These conditions include aneurysmal subarachnoid hemorrhage, pituitary apoplexy, cervical artery dissection, meningitis, and cerebral venous sinus thrombosis. Emergent brain and cerebrovascular imaging must be performed; if imaging is negative for subarachnoid hemorrhage, lumbar puncture can be conducted to definitively exclude subarachnoid hemorrhage or meningitis. In cases of recurrent TCH, brain imaging is still indicated, primarily to investigate for RCVS sequelae, such as convexity (non-aneurysmal) bleeding, lobar hemorrhage, or ischemic stroke.</p>
        <p>The angiographic appearance of affected arteries in RCVS is classically a combination of smoothly tapered narrowing alternating with dilatation, producing the characteristic "sausage on a string" appearance.<xref ref-type="bibr" rid="article-28500.r17">[17]</xref>&#x000a0;Lesions&#x000a0;tend to progress centripetally and are primarily seen in medium to large arteries. While correlations are often modest, transcranial ultrasound can reveal elevated blood flow velocities.<xref ref-type="bibr" rid="article-28500.r2">[2]</xref></p>
      </sec>
      <sec id="article-28500.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Current treatment approaches to RCVS are predicated&#x000a0;on recognizing it as a predominantly benign and self-limited condition. The goal is to avoid misdiagnosis that could lead to unnecessarily invasive investigations, favoring symptomatic treatment over empiric approaches. If triggers are identified, it is crucial to remove them whenever possible until clinical symptoms and imaging findings are resolved.</p>
        <p>The use of long-term antiepileptic agents is generally unwarranted in the absence of irreversible brain injury, even when structural brain lesions are present.&#x000a0;Symptomatic management of headaches and hyperglycemia, which can worsen outcomes, if present, is important. Patients exposed to glucocorticoids should be admitted to a higher level of acuity, such as a step-down unit or ICU. Additionally, the use of laxatives, bed rest, and temporary avoidance of sexual activity may be beneficial.</p>
        <p>Management missteps in the treatment of RCVS include administering vasoconstrictive migraine medications (ie, triptans or ergots) for headaches, empiric use of glucocorticoids for suspected PACNS, and proceeding to brain biopsy or intra-arterial vasodilators to rule out non-RCVS arteriopathies such as vasculitis. Intra-arterial vasodilators only have&#x000a0;temporary effects, and their use can cause reperfusion injury; thus, their use is best avoided.<xref ref-type="bibr" rid="article-28500.r2">[2]</xref></p>
      </sec>
      <sec id="article-28500.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When cerebral angiography reveals a new diagnosis of intracranial arteriopathy, the differential diagnoses include moyamoya disease, intracranial arteriosclerosis, infectious vasculitis, and PACNS.</p>
        <p>PACNS commonly mimics RCVS. Compared to patients with PACNS, those with RCVS are younger (mean age 43 versus 51) and have an approximately 2.6-fold higher percentage of females. Furthermore, an exposure or trigger, such as medications or illicit drugs, as well as physiological stress, is usually identified in patients with RCVS. In patients with PACNS, a trigger is rarely identified. Although headaches are common in both diseases, the nature of the headache differs. In RCVS, the headache typically has a dramatic onset with recurrent TCH. In PACNS, about 50% of patients present with headaches, but only 6% report TCHs.<xref ref-type="bibr" rid="article-28500.r18">[18]</xref></p>
        <p>Imaging is crucial&#x000a0;for diagnosing and differentiating RCVS from PACNS. When compared, patients with RCVS showed abnormalities in initial computed tomography (CT) or MRI scans 70% of the time, whereas patients with PACNS had exclusively abnormal initial CT or MRI. Infarcts are significantly more frequent in PACNS than in RCVS, occurring in 81% and 28% of cases, respectively. Vasogenic edema and convexity subarachnoid hemorrhage are typical features of RCVS but are seldom observed in PACNS. Another notable distinguishing feature is the hyperintense artery sign on the FLAIR sequence of MRI, which appears in approximately 61% of RCVS patients compared to only 7% of PACNS patients.<xref ref-type="bibr" rid="article-28500.r18">[18]</xref></p>
      </sec>
      <sec id="article-28500.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with RCVS precipitated by trauma or surgical procedures, as well as those presenting with focal cortical deficits, are at higher risk of residual neurological deficits. Therefore, close monitoring of these patients is essential.<xref ref-type="bibr" rid="article-28500.r19">[19]</xref></p>
        <p>A portion of patients with RCVS reports mild persistent headaches. Intracranial or subarachnoid hemorrhages typically manifest as early complications, occurring within the first 3 days of headache onset for intracranial bleeds and within 10 days for subarachnoid bleeding. Ischemic stroke most commonly occurs approximately 2 weeks after the onset of headaches in patients who develop this complication.<xref ref-type="bibr" rid="article-28500.r20">[20]</xref></p>
        <p>Many patients with RCVS recover fully without residual symptoms, as vasoconstriction often resolves spontaneously. Clinical and angiographic features may not always resolve concurrently; one may persist without the other and vice versa.<xref ref-type="bibr" rid="article-28500.r14">[14]</xref>&#x000a0;By definition, the duration of symptoms and vasoconstrictor changes in RCVS does&#x000a0;not exceed 3 months and typically resolves within a few weeks.</p>
        <p>Despite the reversible nature of the disease and its generally favorable long-term prognosis, patients can occasionally develop severe vasoconstriction, which may lead to ischemic stroke and, rarely, death.</p>
      </sec>
      <sec id="article-28500.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Significant complications primarily occur within the first week after headache onset in RCVS. These include localized convexity (non-aneurysmal) subarachnoid hemorrhage (22%), leukoencephalopathy (9%), intracerebral hemorrhage (6%), seizure (3%), and transient ischemic attack or ischemic stroke (20%), with the majority of ischemic events occurring in the second week.<xref ref-type="bibr" rid="article-28500.r21">[21]</xref>&#x000a0;These complications can potentially result in permanent residual neurological deficits.<xref ref-type="bibr" rid="article-28500.r22">[22]</xref></p>
      </sec>
      <sec id="article-28500.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>First and foremost, upon diagnosing RCVS, patients should receive education about the condition, emphasizing its usual temporary nature and, above all, its reversibility and typical self-limited nature. In addition, it is essential to counsel patients on potential triggers and emphasize the importance of either avoiding them or promptly informing the healthcare team about their use.</p>
        <p>Furthermore, it is equally important to educate patients about medications used to ameliorate RCVS, especially calcium channel blockers, while emphasizing the need to avoid glucocorticoids, which can potentially worsen outcomes in RCVS.</p>
        <p>Counseling patients to avoid activities that might exacerbate headaches is necessary. Patient education should always be tailored to the individual patient&#x02019;s needs, health literacy level, and preferred learning style. Clear and concise information should be provided, allowing for questions and clarification. If possible, involving family members or other caregivers in the education process is recommended.</p>
      </sec>
      <sec id="article-28500.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Although the association of transient global amnesia with RCVS has not been extensively reported in the literature, there are notable similarities in the triggers of both conditions. This suggests that emotional and physical stress may induce acute neuronal or vascular dysfunction through sympathetic overactivity.<xref ref-type="bibr" rid="article-28500.r23">[23]</xref></p>
        <p>RCVS must be distinguished from PACNS based on the character of the headache, the lesion patterns found on imaging, and the cerebral angiographic appearance of the arteriopathy. RCVS characteristically shows smoothly tapered narrowing and dilatation, whereas PACNS typically exhibits a more notched and irregular appearance.</p>
      </sec>
      <sec id="article-28500.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>RCVS remains underdiagnosed. Clinicians need to recognize the presenting clinical and radiographic features to facilitate prompt diagnosis and avoid unnecessary testing.</p>
        <p>The interprofessional healthcare team typically includes primary care providers, emergency medicine physicians, neurologists, radiologists, pharmacists, and specialty care nurses. Emergency and critical care nurses are crucial in monitoring patients, administering treatments, and updating the team on patient status. Pharmacists review medications used for acute therapy to ensure appropriate dosage and identify potential drug interactions. Nurses assist with procedures, educate patients about the condition, administer medications, and coordinate care between clinicians and pharmacists. This collaborative approach among healthcare professionals is essential for optimizing outcomes and minimizing complications in patients with RCVS.</p>
      </sec>
      <sec id="article-28500.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28500&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28500">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/reversible-cerebral-vasoconstriction-syndromes/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28500">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28500/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28500">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28500.s16">
        <title>References</title>
        <ref id="article-28500.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of reversible cerebral vasoconstriction syndrome.</article-title>
            <source>J Biomed Sci</source>
            <year>2022</year>
            <month>Sep</month>
            <day>21</day>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <pub-id pub-id-type="pmid">36127720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singhal</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome as Syndromes of Cerebrovascular Dysregulation.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>1301</fpage>
            <page-range>1301-1320</page-range>
            <pub-id pub-id-type="pmid">34618761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jumah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Albanna</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reversible Cerebral Vasoconstriction Syndrome Secondary to Loperamide Ingestion: A Case Report.</article-title>
            <source>Neurohospitalist</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>186</fpage>
            <page-range>186-188</page-range>
            <pub-id pub-id-type="pmid">38666269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M M</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jhadav</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Paliwal</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Recurrent thunderclap headache after endovascular embolization of pial AV malformation by onyx material.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>241</volume>
            <fpage>108290</fpage>
            <pub-id pub-id-type="pmid">38663200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Shivashankar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mossa-Basha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Reversible Cerebral Vasoconstriction Syndrome, Part 1: Epidemiology, Pathogenesis, and Clinical Course.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>8</issue>
            <fpage>1392</fpage>
            <page-range>1392-9</page-range>
            <pub-id pub-id-type="pmid">25593203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Fuh</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2010</year>
            <month>May</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-71</page-range>
            <pub-id pub-id-type="pmid">21179608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohyama-Tamagake</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Itami</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Namioka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yatsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murayama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugeno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Misu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adult-onset Leigh Syndrome with a m.9176T&#x0003e;C Mutation Manifested As Reversible Cerebral Vasoconstriction Syndrome.</article-title>
            <source>Intern Med</source>
            <year>2023</year>
            <month>Jul</month>
            <day>01</day>
            <volume>62</volume>
            <issue>13</issue>
            <fpage>1995</fpage>
            <page-range>1995-1998</page-range>
            <pub-id pub-id-type="pmid">36543208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Fuh</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Brain-derived neurotrophic factor gene Val66Met polymorphism modulates reversible cerebral vasoconstriction syndromes.</article-title>
            <source>PLoS One</source>
            <year>2011</year>
            <month>Mar</month>
            <day>18</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>e18024</fpage>
            <pub-id pub-id-type="pmid">21437208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sveinsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Love</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Vilmarsson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Olafsson</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>[Reversible cerebral vasoconstriction syndrome - a common cause of thunderclap headache].</article-title>
            <source>Laeknabladid</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-83</page-range>
            <pub-id pub-id-type="pmid">32009625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burton</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bushnell</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Reversible Cerebral Vasoconstriction Syndrome.</article-title>
            <source>Stroke</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>8</issue>
            <fpage>2253</fpage>
            <page-range>2253-2258</page-range>
            <pub-id pub-id-type="pmid">31272323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spadaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Koyfman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Reversible cerebral vasoconstriction syndrome: A narrative review for emergency clinicians.</article-title>
            <source>Am J Emerg Med</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>50</volume>
            <fpage>765</fpage>
            <page-range>765-772</page-range>
            <pub-id pub-id-type="pmid">34879501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalladka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tyagi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Reversible cerebral vasoconstriction syndrome secondary to caffeine withdrawal.</article-title>
            <source>Scott Med J</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-24</page-range>
            <pub-id pub-id-type="pmid">28480791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gosselin-Lefebvre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pourshahnazari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recurrent thunderclap headaches from reversible cerebral vasoconstriction syndrome associated with duloxetine, xylometazoline and rhinitis medicamentosa.</article-title>
            <source>CMAJ</source>
            <year>2020</year>
            <month>Nov</month>
            <day>09</day>
            <volume>192</volume>
            <issue>45</issue>
            <fpage>E1403</fpage>
            <page-range>E1403-E1406</page-range>
            <pub-id pub-id-type="pmid">33168762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sattar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manousakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of reversible cerebral vasoconstriction syndrome.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>1417</fpage>
            <page-range>1417-21</page-range>
            <pub-id pub-id-type="pmid">20936928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rocha</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Topcuoglu</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>RCVS<sub>2</sub> score and diagnostic approach for reversible cerebral vasoconstriction syndrome.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Feb</month>
            <day>12</day>
            <volume>92</volume>
            <issue>7</issue>
            <fpage>e639</fpage>
            <page-range>e639-e647</page-range>
            <pub-id pub-id-type="pmid">30635475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nannini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Biggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Putoto</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparative Insights to Advance Political Economy Analysis: A Response to Recent Commentaries.</article-title>
            <source>Int J Health Policy Manag</source>
            <year>2023</year>
            <volume>12</volume>
            <fpage>8367</fpage>
            <pub-id pub-id-type="pmid">38618761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perillo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Paolella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perrotta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Serino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caranci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reversible cerebral vasoconstriction syndrome: review of neuroimaging findings.</article-title>
            <source>Radiol Med</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>127</volume>
            <issue>9</issue>
            <fpage>981</fpage>
            <page-range>981-990</page-range>
            <pub-id pub-id-type="pmid">35932443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singhal</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Topcuoglu</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fok</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kursun</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nogueira</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Frosch</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Caviness</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison.</article-title>
            <source>Ann Neurol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>882</fpage>
            <page-range>882-94</page-range>
            <pub-id pub-id-type="pmid">27043703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ducros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koyanagi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Yon</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ghayda</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2021</year>
            <month>May</month>
            <volume>25</volume>
            <issue>9</issue>
            <fpage>3519</fpage>
            <page-range>3519-3529</page-range>
            <pub-id pub-id-type="pmid">34002826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ducros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boukobza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Porcher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sarov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valade</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bousser</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients.</article-title>
            <source>Brain</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>130</volume>
            <issue>Pt 12</issue>
            <fpage>3091</fpage>
            <page-range>3091-101</page-range>
            <pub-id pub-id-type="pmid">18025032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ducros</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reversible cerebral vasoconstriction syndrome.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2014</year>
            <volume>121</volume>
            <fpage>1725</fpage>
            <page-range>1725-41</page-range>
            <pub-id pub-id-type="pmid">24365443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Fuh</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lirng</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Recurrent primary thunderclap headache and benign CNS angiopathy: spectra of the same disorder?</article-title>
            <source>Neurology</source>
            <year>2006</year>
            <month>Dec</month>
            <day>26</day>
            <volume>67</volume>
            <issue>12</issue>
            <fpage>2164</fpage>
            <page-range>2164-9</page-range>
            <pub-id pub-id-type="pmid">17190937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28500.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ducros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The Typical Thunderclap Headache of Reversible Cerebral Vasoconstriction Syndrome and its Various Triggers.</article-title>
            <source>Headache</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>657</fpage>
            <page-range>657-73</page-range>
            <pub-id pub-id-type="pmid">27015869</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
